Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD
Status:
Completed
Trial end date:
2017-08-18
Target enrollment:
Participant gender:
Summary
The aim of the TITAN study is to describe the clinical practices of a cohort of patients with
wAMD refractory to ranibizumab (persistence of intra-retinal and/or subretinal fluid) who
switch to aflibercept after less than 12 months of ranibizumab treatment.
The study will be conducted in real-life conditions and will allow describing conditions of
use of aflibercept in patients refractory to ranibizumab